Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A recent report from the European Commission highlights the increasing importance of payer considerations in demonstrating product value through clinical development programmes.
New studies have affirmed the complexity of genetic changes in solid tumours, but also revealed commonalities in the associated pathways, suggesting that a pathway-oriented perspective could aid cancer drug discovery and therapy.